Dr. LaPelusa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2023 - 2026
- Vanderbilt University Medical CenterResidency, Internal Medicine, 2020 - 2023
- University of Texas Rio Grande Valley School of MedicineClass of 2020, M.D.
Certifications & Licensure
- TX State Medical License 2024 - 2025
- American Board of Internal MedicineInternal Medicine
Publications & Presentations
PubMed
- Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.Shadi Chamseddine, Betul Gok Yavuz, Yehia I Mohamed, Sunyoung S Lee, James C Yao
Journal of Immunotherapy and Precision Oncology. 2024-11-01 - Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.Michael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, Lianchun Xiao, Elshad Hasanov
Oncology. 2024-10-18 - Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report.Shadi Chamseddine, Michael LaPelusa, Kristen Carter, Van Nguyen, Yehia I Mohamed
Journal of Gastrointestinal Oncology. 2024-06-30
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: